Investors

Overview

About ADC Therapeutics

ADC Therapeutics is a commercial-stage global leader and pioneer in the field of antibody drug conjugates (ADCs) advancing proprietary ADC technology to transform the treatment paradigm for patients with hematologic malignancies.

Latest News

Email Alerts

Jun 24, 2026

ADC Therapeutics Announces Strategic Reorganization to Support ZYNLONTA® Growth Opportunities and Regulatory Priorities

Planned ~17% workforce reduction expected to generate annualized estimated savings of approximately $10M, enhancing financial flexibility Company focused on delivering upcoming regulatory and...

Jun 3, 2026

ADC Therapeutics Announces Results From LOTIS-5 Phase 3 Confirmatory Clinical Trial of ZYNLONTA® in Combination with Rituximab in Relapsed or Refractory Diffuse Large B-Cell Lymphoma

ADC Therapeutics SA (NYSE: ADCT) today announced topline data from its Phase 3 LOTIS-5 confirmatory trial evaluating ZYNLONTA® (loncastuximab tesirine-lpyl) in combination with rituximab in...

View All News

Events

Jefferies Global Healthcare Conference

Wednesday, November 19, 2025

12:30pm GMT

Guggenheim Second Annual Healthcare Innovation Conference

Tuesday, November 11, 2025

1:30pm EST

Stephens Biotechnology Virtual Fireside Chats 2025

Monday, November 3, 2025